Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) EBITDA (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of EBITDA data on record, last reported at $15.8 million in Q4 2025.

  • For Q4 2025, EBITDA rose 408.69% year-over-year to $15.8 million; the TTM value through Dec 2025 reached -$14.3 million, up 33.43%, while the annual FY2025 figure was -$14.3 million, 33.43% up from the prior year.
  • EBITDA reached $15.8 million in Q4 2025 per LCTX's latest filing, up from -$3.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $15.8 million in Q4 2025 and bottomed at -$19.8 million in Q2 2025.
  • Average EBITDA over 5 years is -$5.5 million, with a median of -$6.4 million recorded in 2022.
  • The widest YoY moves for EBITDA: up 408.69% in 2025, down 237.14% in 2025.
  • A 5-year view of EBITDA shows it stood at -$6.8 million in 2021, then rose by 2.98% to -$6.6 million in 2022, then rose by 4.17% to -$6.4 million in 2023, then grew by 19.68% to -$5.1 million in 2024, then skyrocketed by 408.69% to $15.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $15.8 million in Q4 2025, -$3.8 million in Q3 2025, and -$19.8 million in Q2 2025.